My belief is that STA-528 exhibits a very promising immune mechanism of action, efficacy in a controlled Phase 2 study with no significant side effects observed, and therefore should be studied in a larger Phase 2B or even Phase 3 clinical study as primary therapy Sincerely,

In short, this seemed to be a very promising compound, given its efficacy, safety potentially broad applicability, ease of use and manufacture.